山东大学学报 (医学版) ›› 2019, Vol. 57 ›› Issue (1): 11-15.doi: 10.6040/j.issn.1671-7554.0.2018.1053
• • 上一篇
朱刚,张凯
ZHU Gang, ZHANG Kai
摘要： 中国前列腺癌发病率呈快速上升趋势。欧洲的大型研究已证实以前列腺特异抗原(PSA)为基础的前列腺癌筛查虽然可以降低前列腺癌死亡率,但是会造成前列腺癌的过度诊断和过度治疗。中国尚缺乏大规模前列腺癌筛查随机对照研究,目前新技术、新方法的出现有望改善前列腺癌筛查现状,但也将面对挑战并需要应对和解决方案。
中图分类号:
| [1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. [2] Wong MC, WB Goggins, HH Wang, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries[J]. Eur Urol, 2016, 70(5): 862-874. [3] Center MM, A Jemal, J Lortet-Tieulent, et al. International variation in prostate cancer incidence and mortality rates[J]. Eur Urol, 2012, 61(6): 1079-1092. [4] Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. [5] US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US preventive services task force recommendation statement[J]. JAMA, 2018, 319(18): 1901-1913. [6] Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study[J]. N Engl J Med, 2009, 360(13): 1320-1328. [7] Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up[J]. N Engl J Med, 2012, 366(11): 981-990. [8] Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer(ERSPC)at 13 years of follow-up[J].The Lancet, 2014, 384(9959): 2027-2035. [9] Zhang K, Bangma CH, Roobol MJ. Prostate cancer screening in Europe and Asia[J]. Asian J Urol, 2017, 4(2): 86-95. [10] Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up[J]. J Natl Cancer Inst, 2012, 104(2): 125-132. [11] Shoag JE, Mittal S, Hu JC. More on reevaluating PSA testing rates in the PLCO trial[J]. N Engl J Med, 2016, 375(15): 1500-1501. [12] Gao HW, Li YL, Wu S, et al. Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen[J]. Asian J Androl, 2005, 7(2): 159-163. [13] Chen R, Sjoberg DD, Huang Y, et al. Prostate specific antigen and prostate cancer in Chinese men undergoing initial prostate biopsies compared with Western cohorts[J]. J Urol, 2017, 197(1): 90-96. [14] Chen R, Ren SC, Chinese Prostate Cancer Consortium, et al. Prostate cancer in Asia: a collaborative report[J]. Asian J Urol, 2014, 1(1): 15-29. [15] Weiner AB, Matulewicz RS, Eggener SE, et al. Increasing incidence of metastatic prostate cancer in the United States(2004-2013)[J]. Prostate Cancer Prostatic Dis, 2016, 19(4): 395-397. [16] Bokhorst LP, Venderbos LD, Schröder FH, et al. Do treatment differences between arms affect the main outcome of ERSPC rotterdam?[J]. J Urol, 2015, 194(2): 336-342. [17] Sartori DA, Chan DW. Biomarkers in prostate cancer: whats new?[J]. Curr Opin Oncol, 2014, 26(3): 259-264. [18] Lughezzani G, Lazzeri M, Haese A, et al. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy[J]. Eur Urol, 2014, 66(5): 906-912. [19] Na R, Ye DW, Liu F, et al. Performance of serum prostate-specific antigen isoform[-2] proPSA(p2PSA)and the prostate health index(PHI)in a Chinese hospital-based biopsy population[J]. Prostate, 2014, 74(15): 1569-1575. [20] Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer[J]. Cancer Res, 1999, 59(23): 5975-5979. [21] Chun FK, de la Taille A, van Poppel H, et al. Prostate cancer gene 3(PCA3): development and internal validation of a novel biopsy nomogram[J]. Eur Urol, 2009, 56(4): 659-667. [22] Chunhua L, Zhao H, Zhao H, et al. Clinical significance of periphreal blood PCA3 gene expression in eraly diagnosis of prostate cancer[J]. Transl Oncol, 2018, 11(3): 628-632. [23] Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer[J]. Eur Urol, 2010, 57(1): 79-85. [24] Chen R, Xie LP, Xue W, et al. Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy[J]. Urol Oncol, 2016, 34(9): 416.e1-7. doi:10.1016/j.urolonc.2016.04.004. [25] Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate imaging - reporting and data system: 2015, version 2[J]. Eur Urol, 2016, 69(1): 16-40. [26] Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012[J]. Eur Radiol, 2012, 22(4): 746-757. [27] Turkbey B, Choyke PL. PIRADS 2.0: what is new?[J]. Diagn Interv Radiol, 2015, 21(5): 382-384. [28] Schoots IG, Roobol MJ, Nieboer D, et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis[J]. Eur Urol, 2015, 68(3): 438-450. [29] 熊轶, 张古田, 汪维, 等. MRI/US成像融合引导的经会阴前列腺穿刺活检的单中心研究[J]. 临床泌尿外科杂志, 2018, 33(1): 39-43. XIONG Yi, ZHANG Gutian, WANG Wei, et al. MRI/US imaging fusion guided transperineal prostate biopsy: a research in single center[J]. Journal of Clinical Urology, 2018, 33(1): 39-43. [30] Bjurlin MA, Mendhiratta N, Wysock JS, et al. Multiparametric MRI and targeted prostate biopsy: Improvements in cancer detection, localization, and risk assessment[J]. Cent European J Urol, 2016, 69(1): 9-18. [31] Wegelin O, van Melick HHE, Hooft L, et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. is there a preferred technique?[J]. Eur Urol, 2017, 71(4): 517-531. [32] Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent[J]. Eur Urol, 2017, 71(4):618-629. [33] Kasivisvanathan V, AS Rannikko, M Borghi, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis[J]. N Engl J Med, 2018, 378(19): 1767-1777. |
| [1] | 王景,谢艳,李培龙,杜鲁涛,王传新. GZMB基因cg16212145位点的异常甲基化芯片测定对胃癌早筛的价值[J]. 山东大学学报 (医学版), 2022, 60(6): 26-34. |
| [2] | 孙浩瑜,姜鑫,陈守臻,曲思凤,史本康. 多参数磁共振联合前列腺健康指数对PSA灰区临床有意义前列腺癌的诊断价值[J]. 山东大学学报 (医学版), 2022, 60(6): 46-50. |
| [3] | 许振,刁统祥,臧振杰,邵丁昌,张奇,孙鼎琪,傅强. 前列腺特异性抗原同源异构体2及其衍生指标在前列腺癌诊断中的价值[J]. 山东大学学报 (医学版), 2022, 60(6): 51-56. |
| [4] | 杨粒芝,孙霄,商蒙蒙,郭鲁,时丹丹,李杰. 基于中国版甲状腺影像报告与数据系统的甲状腺结节恶性风险预测模型[J]. 山东大学学报 (医学版), 2022, 60(6): 64-69. |
| [5] | 苏永刚,王睿,杨同卫. 健康中国视域下老年人群自杀的影响因素及预防对策[J]. 山东大学学报 (医学版), 2022, 60(2): 8-13. |
| [6] | 徐小明,孔裔婷,刘川,明英,况利. 青少年和年轻成人自杀预警系统研究进展[J]. 山东大学学报 (医学版), 2022, 60(2): 69-74. |
| [7] | 史本康,陈守臻,曲思凤,王勇,刘磊. 临床常见快速进展前列腺癌临床特点及研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 110-116. |
| [8] | 徐兵,李勇,刘明,刘永辉. 沉默PRRX1基因表达可增强前列腺癌耐药细胞株PC-3/DTX对多西他赛的敏感性[J]. 山东大学学报 (医学版), 2021, 59(6): 103-110. |
| [9] | 袁媛,徐翠萍,张吉甜. 腹部闭合伤并发高位肠瘘患儿的营养支持1例[J]. 山东大学学报 (医学版), 2021, 59(5): 119-121. |
| [10] | 孙鼎琪,傅强,张辉,刘帅,刁统祥,曹庆伟,张克勤. 多参数磁共振与经直肠超声融合前列腺靶向穿刺活检在检测PI-RADS≥3前列腺癌中的临床价值[J]. 山东大学学报 (医学版), 2021, 59(4): 108-113. |
| [11] | 杨九龙,于涛,薛付忠. 脑血管狭窄患者狭窄分布及筛查模型的建立[J]. 山东大学学报 (医学版), 2021, 59(11): 114-119. |
| [12] | 吕家驹,胡佳林,丁森泰. 前列腺癌局部治疗的研究进展[J]. 山东大学学报 (医学版), 2019, 57(1): 1-5. |
| [13] | 周芳坚,黄华,李永红. 前列腺癌的局灶冷冻治疗[J]. 山东大学学报 (医学版), 2019, 57(1): 6-10. |
| [14] | 杨海霞,成锴,侯茜,张敏,孙明,张林娜. 2015~2017年济南市0~6岁小儿眼病筛查总结与分析[J]. 山东大学学报 (医学版), 2018, 56(9): 41-46. |
| [15] | 刘起勇. 适应和减缓气候变化,保护人类健康福祉[J]. 山东大学学报 (医学版), 2018, 56(8): 3-6. |
|
||
